Monoclonal antibody L4F3 reacts with most acute myeloid leukemia (AML) cells and virtually all normal granulocyte/monocyte colony-forming cells (CFU-GM). Our objective was to determine whether lysis of AML cells with L4F3 and complement allowed expression of normal myeloid progenitors. The five glucose-6-phosphate dehydrogenase (G6PD) heterozygous patients with AML studied manifested only a single G6PD type in blast cells and in most or all granulocyte colony-forming cells, indicating that the leukemias developed clonally. The cells remaining after L4F3 treatment from two of the patients gave rise to granulocytic colonies that expressed the G6PD type not seen in the leukemic clone, indicating that they were derived from normal progenitors (CFU-GM). L4F3-treated cells from these two patients cultured over an irradiated adherent cell layer from normal long-term marrow cultures also gave rise to CFU-GM, which were shown by G6PD analysis to be predominantly nonleukemic. In the other three patients, the progenitor cells remaining after L4F3 treatment were derived mainly from the leukemic clone.
with AML studied manifested only a single G6PD type in blast cells and in most or all granulocyte colony-forming cells, indicating that the leukemias developed clonally. The cells remaining after L4F3 treatment from two of the patients gave rise to granulocytic colonies that expressed the G6PD type not seen in the leukemic clone, indicating that they were derived from normal progenitors (CFU-GM). L4F3-treated cells from these two patients cultured over an irradiated adherent cell layer from normal long-term marrow cultures also gave rise to CFU-GM, which were shown by G6PD analysis to be predominantly nonleukemic. In the other three patients, the progenitor cells remaining after L4F3 treatment were derived mainly from the leukemic clone. The data suggest that in vitro cytolytic treatment with L4F3 of cells from certain patients with AML can enable normal, presumably highly immature progenitors to be expressed. Introduction Recently, monoclonal antibodies directed at normal differentiation antigens present on leukemic cells have been prepared (1, 2) . Certain of these antibodies have been used therapeutically in an attempt to purge malignant cells from marrow in vitro before autologous marrow transplantation (3) (4) (5) . The present study was done to determine whether lysis of hematopoietic cells from patients with acute myeloid leukemia (AML)' with a monoclonal antibody that recognizes normal colony-forming cells and leukemic blast cells would kill leukemic progenitors without affecting all normal progenitors. This might occur ifthe leukemia did not involve stem cells that are more primitive than those recognized by the test antibody.
The monoclonal antibody (L4F3) used in these experiments recognizes a myeloid differentiation antigen found on most AML blasts and colony-forming cells as well as on most normal myeloid colony-forming cells, but is not present on the precursors ofcolony-forming cells detectable in a two-stage long-term marrow cultures system (2, (6) (7) (8) . We determined the effect of L4F3 on circulating hematopoietic progenitor cells from samples of five AML patients heterozygous for glucose-6-phosphate dehydrogenase (G6PD). In such patients, it is possible to determine whether colonies originate from normal or leukemic progenitors. Because of random stable inactivation of one of the two G6PD genes in each somatic cell that occurs as a result of X-chromosome inactivation early in embryogenesis, women heterozygous for the usual G6PD gene (GdB), and a variant such as GdA, have two populations of cells, one synthesizing B-type G6PD and the other, A-type enzyme. If a neoplasm is clonal in such a patient, all neoplastic cells will express a single G6PD type, whereas normal tissues will express both A and B G6PD activities.
We have studied 21 G6PD heterozygous patients with AML (9-12, unpublished data), and Ferraris and co-workers (13, 14) have reported on three others. In each case, blast cells expressed only a single G6PD enzyme whereas noninvolved tissues, such as skin, manifested both A and B type G6PD. These data indicate that AML develops clonally. Additional studies with G6PD suggest that the leukemia is heterogeneous in the pattern of differentiative expression of its cell of origin. In five G6PD heterozygous patients, red cells and platelets manifested only the single G6PD expressed by the blast cells, indicating that the disease involved a stem cell with multilineage differentiative expression (12) (13) (14) . In contrast, in 13 In vitro culture. Peripheral-blood mononuclear cells were plated for CFU-GM and BFU-E growth in the presence of medium conditioned by T cells stimulated by PHA (PHA-LCM) as described (16). After 12-14 d, the colonies were counted with an inverted microscope, harvested, and individually analyzed for G6PD (9) . All colonies or those in a selected area ofa plate were selected independent of size (provided they contained > 40 cells). All colonies were morphologically granulocytic/monocytic or "blastlike."
Two-stage long-term cultures. In this system, test cells are grown over adherent cell layers grown from marrows obtained from normal donors (7, 17) . After antibody-mediated lysis, 0.5-1.0 X 106 mononuclear cells were placed in a 2.0 ml of suspension culture over irradiated (800 cGy) adherent cell layers from 3-5-wk-old long-term marrow cultures derived from normal donor marrow established in "ambitubes" (Lux Plastics). Cultures treated with as little as 400 cGy fail to produce detectable colonyforming cells (17) . Weekly, the cultures were gently agitated by pipetting the supernatant medium several times and then refed after removing one halfofthe supernatant. The culture medium was McCoy's 5A complete medium supplemented with 12.5% fetal calf serum, 12.5% horse serum, and 10' hydrocortisone. Nonadherent cells were washed twice, counted, and plated for CFU-GM growth. The two-stage, long-term cultures were maintained as long as possible but generally were lost after 4-8 wk. When colony-forming cells were grown from these cultures in sufficient numbers, randomly selected colonies were individually plucked and stained with Wright-Giemsa or peroxidase to verify their granulocytic lineage.
Results
Patients studied. As shown in Table I , normal tissues (skin or T lymphocytes) from the five patients manifested both types of G6PD, but only a single enzyme (A or B) was found in the blast cells, indicating that the leukemias were clonal. CFU-GM from all patients expressed predominantly the G6PD type found in the blast cells. In contrast to the leukemic blast cells, both Aand B-type G6PD were detected in erythroid cells (mature red cells in patients 1, 4, and 5; early erythroid progenitors [BFJ-E] in patients 2 and 3). It is presumed that patients 2 and 3 are GdB/GdA-heterozygotes. The A-enzyme is unstable and is usually not detected in mature erythroid cells with the test system we used, but is seen in nucleated red cell precursors, such as BFU-E. The findings of a single G6PD type in leukemic blast Treatment with L4F3 lysed 96±4% (mean±standard deviation) and 98±1% of CFU-GM from patients 1 and 3, respectively. In contrast, only 49% and 44% reductions were observed in patients 4 and 5, respectively. Two experiments on cells from patient 2 led to a 90% and 49% reduction; the first study was performed on fresh cells whereas the second was done with cryopreserved cells. Thus, the lytic effects of antibody L4F3 on CFU-GM were heterogeneous despite the apparently similar levels of stem cell involvement as determined by G6PD expression.
Cells remaining after lysis were plated in semisolid medium and individual colonies were harvested for G6PD analysis to determine whether they originated from malignant or normal stem cells (Table II) . In patient 1, whose leukemic blast cells manifested A-type G6PD, after treatment with control antibody (T 1 D7) the ratio of G6PD A to B colonies was 88:18, notably different from A to B ratio of 60:40 found in normal tissues. In contrast, L4F3-treatment resulted in a colony A to B ratio of 29:16 (pooled results ofexperiments 1-3). This ratio was similar to that found in normal tissue (skin 60:40) but significantly different from the ratio of 88:18 in cells treated with the control (19) . One explanation for this finding is that selection occurred in vitro for cells whose active X chromosome was the one with GdA. This type of selection has been described in vivo (20) (21) (22) .
In studies of the other three patients, the ratios of A to B G6PD in colonies cultured after treatment with L4F3 were not different from those in the control colonies; most colonies expressed only the G6PD enzyme found in the leukemic blast cells. This failure to detect an increase in normal progenitor expression occurred even when growth ofnearly all ofthe colonyforming cells was inhibited by L4F3 (patient 3). Thus, lysis of the majority of the CFU-GM did not necessarily predict that the remaining colony-forming cells would be of normal origin. Moreover, a reduction of < 50% ofcolonies did not predict that those remaining necessarily would be leukemic (patient 2, experiment 2).
Long-term culture assays. To assess the nature of the progenitors remaining after antibody treatment, two-stage long-term marrow cultures were established from mononuclear cells after treatment with either L4F3 or Tl 1D7 and complement. The results of several such experiments are summarized in Table III . Irradiated adherent cell layers cultured alone did not develop hematopoietic islands and did not produce CFU-GM. Similarly, CFU-GM were not detectable when irradiated adherent cells were cultured with irradiated normal marrow cells (data not shown), indicating that stimulation of residual stem cells within the irradiated adherent cell layer by an allogeneic reaction was unlikely.
When cells from patient 1 were treated with L4F3 and complement and placed in suspension over irradiated feeder layers, hematopoietic islands were seen by day 7. In contrast, no morphologic evidence for hematopoietic cell proliferation was observed in the cultures established from Tl lD7-treated cells. CFU-GM were detectable in the supernatant cells ofthe L4F3-treated cultures by week 1 or 2. In two separate long-term culture studies on cells from patient 1, the cumulative culture output of CFU-GM from the L4F3-treated cells was substantially greater than that from the control Tl lD7-treated cells. These differences in colony production reflected both the decay with time of the Tl 1D7 cultures and the increased output of CFU-GM from the L4F3 cultures as they matured. Long-term culture studies on antibody-treated cells from patient 2 yielded similar results to those from patient 1. Tl 1D7-treated cultures failed to produce significant numbers of colonies whereas L4F3-treated cultures produced substantial numbers of CFU-GM for 2 and 8 wk, respectively, in the two experiments. G6PD analysis of colonies from these cultures showed a preponderance of colonies of the nonleukemic G6PD type. The excess of type A colonies grown from the L4F3 culture of patient 2 confirms the supposition that CFU-GM were not derived from the irradiated, type B, adherent cell layer. The differences between the ratios of A to B colonies grown from the L4F3-and the TiID7-treated cultures were statistically significant in all experiments on cells from both patients 1 and 2 (P < 0.01, x2).
Similar experiments were performed on cells from patients 3 and 4 who had failed to express normal CFU-GM in direct culture after treatment with L4F3. When the L4F3-treated cells were established in the two-stage long-term cultures, no morphologic evidence for cell proliferation was observed. Only small numbers of predominantly leukemic colonies were detected.
Discussion
Previous studies with the G6PD system have demonstrated that AML is a heterogeneous disorder. In some patients with this disease, the same single-enzyme G6PD phenotype found in blast cells was also detected in erythrocytes and platelets, indicating that the leukemia arose in a stem cell with multipotent differentiative expression (10-12). However, in other patients, such as the ones studied here, both A-and B-type G6PD were observed in erythroid cells and platelets, whereas only a single enzyme was seen in the leukemic blast cells (8) (9) (10) . Two possibilities could underlie this restriction of expression of the clonal abnormality to overtly leukemic cells: first, the leukemia arose in a multipotent stem cell that was at least partially incapable of differentiating into erythroid cells and platelets; or secondly, the leukemic event affected a progenitor that was already committed to granulocyte/monocyte differentiation (10) . If this latter hypothesis was correct, even immature malignant progenitor cells could express maturation-linked characteristics similar to those of normal stem cells committed to the myeloid pathway.
The present study was performed to determine whether both the normal and the malignant myeloid colony-forming cells in patients with AML expressed the myeloid differentiation antigen recognized by L4F3. This antigen is found on virtually all CFU-GM, some BFU-E, and most mixed colony-forming cells (CFU-GEMM), but not on stem cells that give rise to CFU-GM in vitro (6, 7) . Therefore, treatment with an antibody with specificity for this antigen might result in elimination of both normal and malignant colony-forming cells and leave intact a less mature stem cell compartment that does not express the target antigen and may be completely normal in origin. The present findings are consistent with the hypothesis that treatment with L4F3 eliminated malignant colony-forming progenitors in two of the five patients and allowed outgrowth of normal, granulocyte/ monocyte progenitors. Thus, after treatment with L4F3, the A to B G6PD ratios of CFU-GM-derived colonies from blood mononuclear cells ofpatients 1 and 2 were significantly different from those seen after exposure to the control antibody (T I D7), suggesting that the CFU-GM surviving L4F3 treatment were derived at least in part from nonneoplastic progenitors.
In one experiment on cells from patient 2, the data suggest the possibility that despite an apparent failure oftreatment with L4F3 to eliminate most of the colony-forming cells, remaining progenitor cells may be normal (Table II, (7, 17, 23 It can be calculated that the long-term cultures initiated after L4F3 treatment of cells from each of these patients had colony outputs that substantially exceeded the inputs. However, in cultures established after treatment with the irrelevant antibody, TI 1D7, far fewer colony-forming cells were harvested than were applied.
Colonies cultured after 1 wk in the L4F3-treated long-term cultures from patient I had an A to B G6PD ratio of 74:45, close to the 60:40 ratio found in skin. Colonies grown from L4F3-treated cultures from patient 2 manifested A to B G6PD in a ratio of 89:49 whereas the ratio of A to B G6PD in normal tissues was 50:50 and in the blast cells was mainly of the B type, suggesting that they were not derived from the leukemic clone. In contrast, cells from the control antibody T 1 D7-treated longterm cultures either did not grow (patient 2) or formed colonies that expressed predominantly the same G6PD type as the blast cells (patient 1). It should be noted that in patient 1, experiment 3, and in patient 3, some colony growth was noted in control cultures and the ratio of G6PD A-type colonies to B-type colonies showed a trend towards the predicted normal ratio of G6PD enzymes (Table III) . This finding is consistent with observations by Coulombel et al. (24) and Chang et al. (25) , suggesting that merely culturing chronic myelogenous leukemia or AML cells, respectively, may selectively allow expression of normal progenitor cells. However, in experiment 3 for patient 1, lysis with L4F3 also led to production ofsignificantly more colony-forming cells than was seen in control cultures. Furthermore, in other experiments using cells from patients 1 and 2 there was virtually no growth of cells from control cultures.
The expression of normal colony-forming cells or their production in long-term culture was not increased after cells from the other three patients were treated with L4F3. It is possible that in these patients the leukemia arose in less mature cells, which had not yet acquired the myeloid differentiation antigen recognized by L4F3. If this occurred in patient 3, the putative L4F3-leukemic progenitor cells presumably comprised only a small fraction ofthe leukemic colony-forming cells because L4F3 treatment resulted in a 97% reduction ofleukemic colony growth. Even the small number of unlysed leukemic colony-forming cells in this patient may have been sufficient to inhibit the expression of normal CFU-GM and their precursors. Alternatively, the frequency of normal progenitor cells may have been too low to be detected in our assay system. This possibility is suggested by the inability to culture BFU-E from the blood obtained from patient 4 (only one BFU-E was detected when 2 X 106 non-antibody-treated mononuclear cells were plated).
These 
